👤 Bao-Sen Zhou

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
1335
Articles
847
Name variants
Also published as: Aiping Zhou, Aiwu Zhou, Alicia Y Zhou, An Zhou, Ang Zhou, Anna Y Zhou, Annan Zhou, Ao Zhou, Aojia Zhou, Aoshuang Zhou, Apei Zhou, Baiwan Zhou, Baohua Zhou, Baojuan Zhou, Baosen Zhou, Beixian Zhou, Beiyi Zhou, Bin Zhou, Bincheng Zhou, Bing Zhou, Bingbing Zhou, Binghai Zhou, Bingqian Zhou, Bingqing Zhou, Bingying Zhou, Binhua P Zhou, Binhua Zhou, Birong Zhou, Bo Zhou, Bo-Ya Zhou, Bo-Yang Zhou, Bubo Zhou, C Zhou, C-J Zhou, Can Zhou, Carl Zhou, Cefan Zhou, Chang Zhou, Chang-Yin Zhou, Changfan Zhou, Changhua Zhou, Changqi Zhou, Changrui Zhou, Changshuai Zhou, Changwen Zhou, Chao Zhou, Chen-Hui Zhou, Chen-Liang Zhou, Chenchen Zhou, Cheng Zhou, Chengji J Zhou, Chenhao Zhou, Chenkang Zhou, Chenqi Zhou, Chenxia Zhou, Chong Zhou, Chong-zhi Zhou, Chongwei Zhou, ChuHuan Zhou, Chuan-Min Zhou, Chuan-Wei Zhou, Chuan-Xiang Zhou, Chuan-chuan Zhou, Chuanen Zhou, Chuanman Zhou, Chuhao Zhou, Chun-Man Zhou, Chun-Ni Zhou, Chunlei Zhou, Chunlin Zhou, Chunni Zhou, Chunxian Zhou, Chunxiu Zhou, Chunyu Zhou, Chunzhuang Zhou, Chuyu Zhou, Cui Zhou, Cuiqi Zhou, Da Zhou, Daijun Zhou, Daizhan Zhou, Dan Zhou, Danmei Zhou, Danxia Zhou, Dao Zhou, David Zhou, Dawei Zhou, Daxin Zhou, Degang Zhou, Dejun Zhou, Dezheng Zhou, Dingan Zhou, Dingzi Zhou, Dong-Sheng Zhou, Dongdong Zhou, Donger Zhou, Dongfang Zhou, Donghai Zhou, Dongjie Zhou, Dongmei Zhou, Dongsheng Zhou, Duanfang Zhou, Duo-Qi Zhou, Duoqi Zhou, Enchen Zhou, Ershun Zhou, F Zhou, Fachen Zhou, Fan Zhou, Fanfan Zhou, Fang Zhou, Fangfang Zhou, Fangli Zhou, Fangting Zhou, Fei Zhou, Feixue Zhou, Feiye Zhou, Feng Zhou, Feng-Quan Zhou, Fenghua Zhou, Fengrui Zhou, Fengyun Zhou, Fenling Zhou, Fu-Ling Zhou, Fude Zhou, Fuling Zhou, Fusheng Zhou, Fuxiang Zhou, Fuyou Zhou, G Zhou, Gang Zhou, Grace Guoying Zhou, Guangji Zhou, Guangjun Zhou, Guangming Zhou, Guangqian Zhou, Guangzhou Zhou, Gui-Feng Zhou, Guifeng Zhou, Guiju Zhou, Guili Zhou, Guiting Zhou, Guo Zhou, Guo-Kun Zhou, Guohong Zhou, Guohua Zhou, Guoli Zhou, Guoyu Zhou, Guyue Zhou, H Zhou, Haibo Zhou, Haihong Zhou, Haihua Zhou, Haijing Zhou, Haimei Zhou, Hairui Zhou, Haixu Zhou, Haiyan Zhou, Haiyuan Zhou, Haiyue Zhou, Han Zhou, Hang Zhou, Hang-Yu Zhou, Hangfan Zhou, Hanshen Zhou, Hanxiao Zhou, Hao Zhou, Hao-Min Zhou, Haobo Zhou, Haonan Zhou, Haoxiong Zhou, Haoyuan Zhou, He Zhou, Helen Zhou, HengCui Zhou, Heying Zhou, Hong Zhou, Hong-Yu Zhou, Honghong Zhou, Hongji Zhou, Honglei Zhou, Hongli Zhou, Hongmei Zhou, Hongmin Zhou, Hongshan Zhou, Hongwei Zhou, Hongwen Zhou, Hongyan Zhou, Hou-De Zhou, Hu Zhou, Hua Ying Zhou, Hua Zhou, Hua-Bang Zhou, Huadong Zhou, Huaijun Zhou, Huamao Zhou, Huan Zhou, Huangao Zhou, Huanjin Zhou, Huanyu Zhou, Huaqiang Zhou, Hui Zhou, Hui-Fen Zhou, Huifang Zhou, Huifen Zhou, Huihui Zhou, Huimin Zhou, Huinian Zhou, Huiqiang Zhou, Huiwen Zhou, J Zhou, Jeff Xiwu Zhou, Ji Zhou, Ji-Chao Zhou, Ji-Ying Zhou, Jia Zhou, Jia-Guo Zhou, Jia-le Zhou, Jiahe Zhou, Jiahua Zhou, Jiajie Zhou, Jiale Zhou, Jiamei Zhou, Jian Zhou, Jian-Peng Zhou, JianJiang Zhou, Jianan Zhou, Jianfen Zhou, Jianfeng Zhou, Jiang-Ning Zhou, Jiangfei Zhou, Jianghao Zhou, Jianghong Zhou, Jianghui Zhou, Jianglin Zhou, Jiangqiao Zhou, Jianguo Zhou, Jianhua Zhou, Jianling Zhou, Jianmin Zhou, Jianqing Zhou, Jianshe Zhou, Jianwei Zhou, Jianying Zhou, Jianzhong Zhou, Jiaqi Zhou, Jiaru Zhou, Jiawang Zhou, Jiawei Zhou, Jiawen Zhou, Jiaxi Zhou, Jiaxiang Zhou, Jiaxin Zhou, Jiayan Zhou, Jiayi Zhou, Jiayin Zhou, Jie Zhou, Jiechao Zhou, Jiefu Zhou, Jieru Zhou, Jieyan Zhou, Jieyu Zhou, Jin Zhou, Jin-Ting Zhou, Jin-Yong Zhou, JinQiu Zhou, Jing Zhou, Jing-Wei Zhou, Jing-Xuan Zhou, Jingbo Zhou, Jingjie Zhou, Jingjing Zhou, Jingjun Zhou, Jingpei Zhou, Jingqi Zhou, Jingwen Zhou, Jingyi Zhou, Jingyu Zhou, Jingyuan Zhou, Jinting Zhou, Jinyi Zhou, Jiuyao Zhou, Jiyong Zhou, John Zhou, Ju Zhou, Juan Zhou, Juanjuan Zhou, Jue-Yu Zhou, Julian Q Zhou, Jun Zhou, Jun-Min Zhou, Jun-Ying Zhou, Jun-Yu Zhou, Jundong Zhou, Junfeng Zhou, Jungu Zhou, Junguo Zhou, Junhe Zhou, Junjie Zhou, Junjun Zhou, Junting Zhou, Junya Zhou, Junyu Zhou, Justin Zhou, Juying Zhou, Kaicheng Zhou, Kaixia Zhou, Kaixin Zhou, Kaiyu Zhou, Kan Zhou, Ke Zhou, Kecheng Zhou, Kefu Zhou, Kejin Zhou, Kexun Zhou, Lamei Zhou, Lan Zhou, Lang Zhou, Lanlan Zhou, Lanping Zhou, Lanqi Zhou, Laura Y Zhou, Le Zhou, Lei Zhou, Lei-Lei Zhou, Li Zhou, Li-Jun Zhou, Liang Zhou, Liangdong Zhou, Liangfu Zhou, Liangrui Zhou, Liangxue Zhou, Liangyu Zhou, Libin Zhou, Libing Zhou, Libo Zhou, Liche Zhou, Lihong Zhou, Lihuan Zhou, Lijun Zhou, Lili Zhou, Limin Zhou, Lin Zhou, Lina Zhou, Linda Zhou, Ling Zhou, Ling-Yun Zhou, Linglin Zhou, Lingshan Zhou, Lingyi Zhou, Lingyun Zhou, Linjun Zhou, Linnan Zhou, Linran Zhou, Lipeng Zhou, Liqun Zhou, Lisha Zhou, Lisheng Zhou, Liting Zhou, Liufang Zhou, Liuqing Zhou, Liuxin Zhou, Lixin Zhou, Liye Zhou, Long Zhou, Lu Zhou, Lufang Zhou, Luling Zhou, Luming Zhou, Lunni Zhou, Luo-Qi Zhou, Luting Zhou, M M Zhou, Maoge Zhou, Maotian Zhou, Mei Zhou, Meijing Zhou, Meilan Zhou, Meiqi Zhou, Meirong Zhou, Meiyi Zhou, Meng-Tao Zhou, Meng-Yao Zhou, Menghua Zhou, Mengkai Zhou, Menglong Zhou, Mengna Zhou, Mengqi Zhou, Mengqian Zhou, Mengze Zhou, Mi Zhou, Miao Zhou, Min Zhou, Ming Zhou, Ming-Ju Zhou, Ming-Ming Zhou, Ming-Sheng Zhou, Mingfeng Zhou, Minglei Zhou, Minglian Zhou, Mingmei Zhou, Mingming Zhou, Mingping Zhou, Mingqi Zhou, Minling Zhou, Minyi Zhou, Molin Zhou, Na Zhou, Nan Zhou, Neng Zhou, Ni Zhou, Nian Zhou, Nianwei Zhou, Ning Zhou, Ningying Zhou, Niuniu Zhou, P Zhou, Pei Zhou, Peng Zhou, Penghui Zhou, Pijun Zhou, Ping Zhou, Ping-Kun Zhou, Pingkun Zhou, Pingxi Zhou, Pingxin Zhou, Puhui Zhou, Q Zhou, Qi Zhou, Qian Zhou, Qiang Zhou, Qianxin Zhou, Qiao Zhou, Qiaoxia Zhou, Qidong Zhou, Qin Zhou, Qin-Yi Zhou, Qing Zhou, Qing-Bing Zhou, Qing-Qing Zhou, Qingbing Zhou, Qingbo Zhou, Qingchun Zhou, Qinghua Zhou, Qingniao Zhou, Qingnv Zhou, Qingping Zhou, Qingtong Zhou, Qingxin Zhou, Qingyu Zhou, Qiong Zhou, Qiu-Min Zhou, Qiu-Zhi Zhou, Qiyang Zhou, Qiyin Zhou, Quan Zhou, Qun Zhou, R B Zhou, Ranran Zhou, Raorao Zhou, Ren Zhou, Rong Zhou, Rong-Yan Zhou, Rongbin Zhou, Rongjia Zhou, Rongxian Zhou, Rongxuan Zhou, Rongyan Zhou, Rouxi Zhou, Ru Zhou, Ruchen Zhou, Rui Zhou, Ruihai Zhou, Ruijun Zhou, Ruimei Zhou, Ruisi Zhou, Runjin Zhou, Ruyi Zhou, S A Zhou, S R Zhou, S Zhou, S-G Zhou, Sa Zhou, Sanshun Zhou, Sha Zhou, Shanshan Zhou, Shao-Lai Zhou, Shaobo Zhou, Shaoli Zhou, Shaolong Zhou, Sheng-Nan Zhou, Shenghua Zhou, Shenghui Zhou, Shengwen Zhou, Shengyang Zhou, Shengyi Zhou, Shenping Zhou, Shiao Zhou, Shibo Zhou, Shiyi Zhou, Shu Zhou, Shuaishuai Zhou, Shuaiyang Zhou, Shuang Zhou, Shuling Zhou, Shumin Zhou, Shun Zhou, Shuo Zhou, Si Zhou, Si-Qi Zhou, Siquan Zhou, Sirui Zhou, Song Zhou, Songhui Zhou, Sufang Zhou, Sumei Zhou, Suqing Zhou, Suzhen Zhou, T Zhou, Tai-Cheng Zhou, Taimei Zhou, Tao Zhou, Tengxiao Zhou, Ti Zhou, Tian-Li Zhou, Tianhua Zhou, Tianqiong Zhou, Tianrong Zhou, Tianxing Zhou, Tianyan Zhou, Tianyu Zhou, Tiger Zhou, Ting Zhou, Tingting Zhou, Tong Zhou, Vincent Zhou, W Zhou, Wan-hao Zhou, Wang Zhou, Wei Zhou, Weihua Zhou, Weihui Zhou, Weijiao Zhou, Weijie Zhou, Weiming Zhou, Weinan Zhou, Weiqiang Zhou, Weishang Zhou, Weiwei Zhou, Weiying Zhou, Wen Zhou, Wen-Chao Zhou, Wen-Hao Zhou, Wen-Jie Zhou, Wen-Quan Zhou, Wenbin Zhou, Wenbo Zhou, Wenchao Zhou, Wenfang Zhou, Wenhao Zhou, Wenjie Zhou, Wenjing Zhou, Wenke Zhou, Wenqing Zhou, Wenrong Zhou, Wenwen Zhou, Wenxing Zhou, Wenyu Zhou, Wenzong Zhou, Wesley Zhou, Wu Zhou, Wuduo Zhou, Wuyuan Zhou, X F Zhou, X Q Zhou, X-T Zhou, Xi Zhou, Xia Zhou, Xia-Bo Zhou, Xiang Zhou, Xiangda Zhou, Xiangdong Zhou, Xianghai Zhou, Xiangrong Zhou, Xianguo Zhou, Xiangyu Zhou, Xiangyuan Zhou, Xianhu Zhou, Xianhua Zhou, Xianhui Zhou, Xianjing Zhou, Xianliang Zhou, Xianxiao Zhou, Xiao Zhou, Xiao-Hai Zhou, Xiao-Ting Zhou, Xiao-Yu Zhou, Xiaobo Zhou, Xiaochuan Zhou, Xiaochun Zhou, Xiaofeng Zhou, Xiaohai Zhou, Xiaohan Zhou, Xiaohui Zhou, Xiaojing Zhou, Xiaolei Zhou, Xiaoli Zhou, Xiaolin Zhou, Xiaoling Zhou, Xiaomao Zhou, Xiaoming Zhou, Xiaonan Zhou, Xiaopu Zhou, Xiaoqian Zhou, Xiaorong Zhou, Xiaorui Zhou, Xiaoshu Zhou, Xiaosu Zhou, Xiaotong Zhou, Xiaowen Zhou, Xiaoxi Zhou, Xiaoxia Zhou, Xiaoxue Zhou, Xiaoyan Zhou, Xiaoye Zhou, Xiaoying Zhou, Xiaozhong Zhou, Xidan Zhou, Xin Tong Zhou, Xin Zhou, Xin-Rong Zhou, Xin-Yu Zhou, Xin-Yue Zhou, Xingtao Zhou, Xinhong Zhou, Xinhua Zhou, Xinming Zhou, Xinyan Zhou, Xinyao Zhou, Xinyi Zhou, Xinyue Zhou, Xinzhi Zhou, Xiqiu Zhou, Xiu-Ping Zhou, Xiuhong Zhou, Xiuling Zhou, Xiuping Zhou, Xiuteng Zhou, Xiyi Zhou, Xu Yu Zhou, Xu Zhou, Xu-Hua Zhou, Xuan Zhou, Xuanchen Zhou, Xuchang Zhou, Xue Dong Zhou, Xue Zhou, Xue-Yan Zhou, Xuedong Zhou, Xuefeng Zhou, Xuejie Zhou, Xueli Zhou, Xueliang Zhou, Xueqin Zhou, Xueqing Zhou, Xueshi Zhou, Xujie Zhou, Xun Zhou, Xuyu Zhou, Y J Zhou, Y Zhou, Y-L Zhou, Yachuan Zhou, Yadi Zhou, Yahui Zhou, Yajun Zhou, Yan Zhou, Yan-Yan Zhou, Yanbing Zhou, Yandong Zhou, Yanfen Zhou, Yang Zhou, Yangbo Zhou, Yangying Zhou, Yanhao Zhou, Yanheng Zhou, Yanhua Zhou, Yanjiao Zhou, Yanjie Zhou, Yanli Zhou, Yanling Zhou, Yanmeng Zhou, Yanqiu Zhou, Yanrong Zhou, Yanyi Zhou, Yao Zhou, Yaping Zhou, Yaqi Zhou, Yating Zhou, Yeyun Zhou, Yi Zhou, Yi-Hui Zhou, Yi-Jiang Zhou, Yichao Zhou, Yidan Zhou, Yifa Zhou, Yifeng Zhou, Yinan Zhou, Ying Zhou, Ying-Hui Zhou, Yinghui Zhou, Yingjie Zhou, Yingmin Zhou, Yingshi Zhou, Yiqing Zhou, Yitian Zhou, Yong Zhou, Yong-Gang Zhou, Yong-Hui Zhou, Yong-an Zhou, Yongbing Zhou, Yongcan Zhou, Yonghua Zhou, Yongjian Zhou, Yongqiang Zhou, Yongtao Zhou, Yongxin Zhou, Yongzhi Zhou, You Lang Zhou, You Zhou, You-Li Zhou, Youping Zhou, Yu Zhou, Yu-Bao Zhou, Yu-Ning Zhou, Yu-Qi Zhou, Yuan Zhou, Yuanyuan Zhou, Yubin Zhou, Yudong Zhou, Yue Zhou, Yueping Zhou, Yuetao Zhou, Yufei Zhou, Yuhan Zhou, Yuhuan Zhou, Yujia Zhou, Yujie Zhou, Yun Zhou, Yun-Fei Zhou, Yun-Tao Zhou, Yunfang Zhou, Yunfeng Zhou, Yunhui Zhou, Yunqian Zhou, Yunxia Zhou, Yunxiang Zhou, Yunyun Zhou, Yunzhen Zhou, Yuqi Zhou, Yuqiao Zhou, Yuqing Zhou, Yuqiu Zhou, Yushan Zhou, Yuting Zhou, Yutong Zhou, Yuxin Zhou, Yuzhi Zhou, Zechen Zhou, Zefeng Zhou, Zenghui Zhou, Zengyuan Zhou, Zengzi Zhou, Zewei Zhou, Zhan Zhou, Zhaokai Zhou, Zhechong Zhou, Zhen Zhou, Zheng Zhou, Zheng-Jun Zhou, Zheng-Yang Zhou, Zhengyang Zhou, Zhengzhong Zhou, Zhenhua Zhou, Zhenlei Zhou, Zhenying Zhou, Zhenyu Zhou, Zheyi Zhou, Zhi Dong Zhou, Zhi Zhou, Zhi-Dong Zhou, Zhi-Gang Zhou, Zhi-Hang Zhou, Zhi-Jiao Zhou, Zhi-Xiang Zhou, Zhi-Yong Zhou, Zhibo Zhou, Zhicheng Zhou, Zhifeng Zhou, Zhiguang Zhou, Zhihang Zhou, Zhihao Zhou, Zhiheng Zhou, Zhihui Zhou, Zhijiao Zhou, Zhijun Zhou, Zhimin Zhou, Zhipeng Zhou, Zhiqin Zhou, Zhiqun Zhou, Zhiwei Zhou, Zhixiang Zhou, Zhiyi Zhou, Zhiyong Zhou, Zhiyu Zhou, Zhongbo Zhou, Zhongjiang Zhou, Zhongkai Zhou, Zhongqiu Zhou, Zhongtao Zhou, Zhongxing Zhou, Zhongyin Zhou, Zhou Zhou, Zhu Zhou, Zhuoming Zhou, Zi-Yang Zhou, Zi-Yi Zhou, Zihan Zhou, Zihao Zhou, Zihua Zhou, Zijun Zhou, Zili Zhou, Ziliang Zhou, Zilin Zhou, Zilong Zhou, Zipeng Zhou, Ziqing Zhou, Ziwei Zhou, Ziyan Zhou, Ziyue Zhou, Ziyun Zhou, Zongkai Zhou, Zunchun Zhou, Zuomin Zhou, Zuoqiong Zhou, Zuping Zhou
articles
Fenghui Zhao, Chao Zhang, Qingtong Zhou +15 more · 2021 · eLife · added 2026-04-24
Glucose-dependent insulinotropic polypeptide (GIP) is a peptide hormone that exerts crucial metabolic functions by binding and activating its cognate receptor, GIPR. As an important therapeutic target Show more
Glucose-dependent insulinotropic polypeptide (GIP) is a peptide hormone that exerts crucial metabolic functions by binding and activating its cognate receptor, GIPR. As an important therapeutic target, GIPR has been subjected to intensive structural studies without success. Here, we report the cryo-EM structure of the human GIPR in complex with GIP and a G Show less
📄 PDF DOI: 10.7554/eLife.68719
GIPR
Chun Han, Yuqing Sun, Qimeng Yang +5 more · 2021 · Molecular pharmaceutics · ACS Publications · added 2026-04-24
Novel peptidic glucagon receptor (GCGR) and glucagon-like peptide 1 receptor (GLP-1R) dual agonists are reported to have increased efficacy over GLP-1R monoagonists for the treatment of diabetes and o Show more
Novel peptidic glucagon receptor (GCGR) and glucagon-like peptide 1 receptor (GLP-1R) dual agonists are reported to have increased efficacy over GLP-1R monoagonists for the treatment of diabetes and obesity. We identified a novel Show less
no PDF DOI: 10.1021/acs.molpharmaceut.0c00995
GIPR
Yang Zhou, Monica K Chawla, Jose L Rios-Monterrosa +5 more · 2021 · Molecules (Basel, Switzerland) · MDPI · added 2026-04-24
Brain G-protein coupled receptors have been hypothesized to be potential targets for maintaining or restoring cognitive function in normal aged individuals or in patients with neurodegenerative diseas Show more
Brain G-protein coupled receptors have been hypothesized to be potential targets for maintaining or restoring cognitive function in normal aged individuals or in patients with neurodegenerative disease. A number of recent reports suggest that activation of melanocortin receptors (MCRs) in the brain can significantly improve cognitive functions of normal rodents and of different rodent models of the Alzheimer's disease. However, the potential impact of normative aging on the expression of MCRs and their potential roles for modulating cognitive function remains to be elucidated. In the present study, we first investigated the expression of these receptors in six different brain regions of young (6 months) and aged (23 months) rats following assessment of their cognitive status. Correlation analysis was further performed to reveal potential contributions of MCR subtypes to spatial learning and memory. Our results revealed statistically significant correlations between the expression of several MCR subtypes in the frontal cortex/hypothalamus and the hippocampus regions and the rats' performance in spatial learning and memory only in the aged rats. These findings support the hypothesis that aging has a direct impact on the expression and function of MCRs, establishing MCRs as potential drug targets to alleviate aging-induced decline of cognitive function. Show less
📄 PDF DOI: 10.3390/molecules26206266
MC4R
Huibing Zhang, Li-Nan Chen, Dehua Yang +14 more · 2021 · Cell research · Nature · added 2026-04-24
Melanocortin-4 receptor (MC4R) plays a central role in the regulation of energy homeostasis. Its high sequence similarity to other MC receptor family members, low agonist selectivity and the lack of s Show more
Melanocortin-4 receptor (MC4R) plays a central role in the regulation of energy homeostasis. Its high sequence similarity to other MC receptor family members, low agonist selectivity and the lack of structural information concerning MC4R-specific activation have hampered the development of MC4R-seletive therapeutics to treat obesity. Here, we report four high-resolution structures of full-length MC4R in complex with the heterotrimeric G Show less
no PDF DOI: 10.1038/s41422-021-00552-3
MC4R
Sapana R Gupta, Yingjie Zhou, Thomas A Wadden +2 more · 2021 · Obesity surgery · Springer · added 2026-04-24
This systematic review synthesized research evaluating the relationship between genetic predictors and weight loss after bariatric surgery. Fifty-seven studies were identified that examined single gen Show more
This systematic review synthesized research evaluating the relationship between genetic predictors and weight loss after bariatric surgery. Fifty-seven studies were identified that examined single genes or genetic risk scores. Uncoupling protein (UCP) rs660339 was associated with excess weight loss after surgery in 4 of 6 studies. The most commonly assessed genes were fat mass and obesity-associated (FTO) gene (n = 10) and melanocortin-4 receptor (MC4R) (n = 14). Both were inconsistently related to weight loss. Genetic risk scores predicted weight loss in 6 of 7 studies. This evidence suggests the potential of using genetic variants and genetic risk scores to predict the amount of weight loss anticipated after bariatric surgery and identify patients who may be at risk for suboptimal weight reduction. Show less
📄 PDF DOI: 10.1007/s11695-021-05585-6
MC4R
Wenyu Ding, Changjiang Zhang, Baisong Wang +7 more · 2021 · Science China. Life sciences · Springer · added 2026-04-24
Cenpj is a centrosomal protein located at the centrosomes and the base of cilia, it plays essential roles in regulating neurogenesis and cerebral cortex development. Although centrosomal and cilium dy Show more
Cenpj is a centrosomal protein located at the centrosomes and the base of cilia, it plays essential roles in regulating neurogenesis and cerebral cortex development. Although centrosomal and cilium dysfunction are one of the causes of obesity, insulin resistance, and type 2 diabetes, the role that Cenpj plays in the regulation of body weight remains unclear. Here, we deleted Cenpj by crossing Cenpj Show less
no PDF DOI: 10.1007/s11427-020-1767-5
MC4R
Yin-Hong Cao, Song-Song Xu, Min Shen +39 more · 2021 · Molecular biology and evolution · Oxford University Press · added 2026-04-24
How animals, particularly livestock, adapt to various climates and environments over short evolutionary time is of fundamental biological interest. Further, understanding the genetic mechanisms of ada Show more
How animals, particularly livestock, adapt to various climates and environments over short evolutionary time is of fundamental biological interest. Further, understanding the genetic mechanisms of adaptation in indigenous livestock populations is important for designing appropriate breeding programs to cope with the impacts of changing climate. Here, we conducted a comprehensive genomic analysis of diversity, interspecies introgression, and climate-mediated selective signatures in a global sample of sheep and their wild relatives. By examining 600K and 50K genome-wide single nucleotide polymorphism data from 3,447 samples representing 111 domestic sheep populations and 403 samples from all their seven wild relatives (argali, Asiatic mouflon, European mouflon, urial, snow sheep, bighorn, and thinhorn sheep), coupled with 88 whole-genome sequences, we detected clear signals of common introgression from wild relatives into sympatric domestic populations, thereby increasing their genomic diversities. The introgressions provided beneficial genetic variants in native populations, which were significantly associated with local climatic adaptation. We observed common introgression signals of alleles in olfactory-related genes (e.g., ADCY3 and TRPV1) and the PADI gene family including in particular PADI2, which is associated with antibacterial innate immunity. Further analyses of whole-genome sequences showed that the introgressed alleles in a specific region of PADI2 (chr2: 248,302,667-248,306,614) correlate with resistance to pneumonia. We conclude that wild introgression enhanced climatic adaptation and resistance to pneumonia in sheep. This has enabled them to adapt to varying climatic and environmental conditions after domestication. Show less
📄 PDF DOI: 10.1093/molbev/msaa236
ADCY3
Xingyue Yang, Wenyan Sun, Qian Wu +9 more · 2021 · Nutrients · MDPI · added 2026-04-24
Use of folic acid (FA) during early pregnancy protects against birth defects. However, excess FA has shown gender-specific neurodevelopmental toxicity. Previously, we fed the mice with 2.5 times the r Show more
Use of folic acid (FA) during early pregnancy protects against birth defects. However, excess FA has shown gender-specific neurodevelopmental toxicity. Previously, we fed the mice with 2.5 times the recommended amount of FA one week prior to mating and during the pregnancy and lactation periods, and detected the activated expression of Show less
📄 PDF DOI: 10.3390/nu14010066
ANGPTL4
Liang Zhou, Guangyan Xu, Li Wang +2 more · 2021 · Disease markers · added 2026-04-24
An interaction between hypoxia and immunity has been confirmed in tumor tissue. However, there is no combined biomarker for diagnosis on this basis. Therefore, we developed a scoring formula based on Show more
An interaction between hypoxia and immunity has been confirmed in tumor tissue. However, there is no combined biomarker for diagnosis on this basis. Therefore, we developed a scoring formula based on markers of hypoxia and immunity. Firstly, the hypoxia-immune formula of lung adenocarcinoma (LUAD) was derived using LASSO-Cox regression in three cohorts from public database, and the corresponding score was calculated for each patient. The formula is as follows: combined hypoxia and immune index (CIHI) = LDHA expression × 0.2252 + GAPDH expression × 0.0727 + ANGPTL4 expression × 0.0724 + VEGFC expression × 0.1911 + DKK1 expression × 0.1355 + ADM expression × 0.0588 + BTK expression × -0.1659. Meanwhile, patients were divided into groups according to high and low CIHI, and expression profiles of hypoxia markers and immune markers were analyzed in different groups. CIHI was used to confirm that patients with high CIHI represented a state of hypoxia Show less
📄 PDF DOI: 10.1155/2021/4495489
ANGPTL4
Xin Zheng, Rui Liu, Chenchen Zhou +12 more · 2021 · Cancer research · added 2026-04-24
Colorectal cancer is a severe health problem worldwide, and accumulating evidence supports the contribution of
📄 PDF DOI: 10.1158/0008-5472.CAN-21-2273
ANGPTL4
Yi-Zhang Liu, Chi Zhang, Jie-Feng Jiang +5 more · 2021 · Clinica chimica acta; international journal of clinical chemistry · Elsevier · added 2026-04-24
Atherosclerosis, as a chronic inflammatory disease within the arterial wall, is a leading cause of morbidity and mortality worldwide due to its role in myocardial infarction, stroke and peripheral art Show more
Atherosclerosis, as a chronic inflammatory disease within the arterial wall, is a leading cause of morbidity and mortality worldwide due to its role in myocardial infarction, stroke and peripheral artery disease. Additional evidence is emerging that the angiopoietin-like (ANGPTL) family of proteins participate in the pathology of this disease process via endothelial dysfunction, inflammation, dyslipidemia, calcification, foam cell formation and platelet activation. This review summarizes current knowledge on the ANGPTL family of proteins in atherosclerosis related pathological processes. Moreover, the potential value of ANGPTL family proteins as predictive biomarkers in atherosclerosis is discussed. Given the attractive role of ANGPTL3, ANGPTL4, ANGPTL8 in atherosclerotic dyslipidemia via regulation of lipoprotein lipase (LPL), antisense oligonucleotide or/and monoclonal antibody-based inactivation of these proteins represent potential atherosclerotic therapies. Show less
no PDF DOI: 10.1016/j.cca.2021.06.024
ANGPTL4
Hua Zhou, Bing Yu, Jing Sun +4 more · 2021 · Journal of animal science and biotechnology · BioMed Central · added 2026-04-24
Previous studies have shown that exogenous short-chain fatty acids (SCFAs) introduction attenuated the body fat deposition in conventional mice and pigs. However, limited studies have evaluated the ef Show more
Previous studies have shown that exogenous short-chain fatty acids (SCFAs) introduction attenuated the body fat deposition in conventional mice and pigs. However, limited studies have evaluated the effects of exogenously introduced SCFAs on the lipid and glucose metabolism independently of the gut microbiota. This study was to investigate the effects of exogenous introduction of SCFAs on the lipid and glucose metabolism in a germ-free (GF) pig model. Twelve hysterectomy-derived newborn pigs were reared in six sterile isolators. All pigs were hand-fed with sterile milk powder for 21 d, then the sterile feed was introduced to pigs for another 21 d. In the second 21-d period, six pigs were orally administrated with 25 mL/kg sterile saline per day and considered as the GF group, while the other six pigs were orally administrated with 25 mL/kg SCFAs mixture (acetic, propionic, and butyric acids, 45, 15, and 11 mmol/L, respectively) per day and regarded as FA group. Orally administrated with SCFAs tended to increase the adiponectin concentration in serum, enhance the CPT-1 activity in longissimus dorsi, and upregulate the ANGPTL4 mRNA expression level in colon (P < 0.10). Meanwhile, the mRNA abundances of ACC, FAS, and SREBP-1C in liver and CD36 in longissimus dorsi of the FA group were decreased (P < 0.05) compared with those in the GF group. Besides, the mRNA expression of PGC-1α in liver and LPL in longissimus dorsi tended to (P < 0.10) upregulate and downregulate respectively in the FA group. Moreover, oral administration of SCFAs tended to increase the protein level of GPR43 (P < 0.10) and decrease the protein level of ACC (P < 0.10) in liver. Also, oral administration of SCFAs upregulated the p-AMPK/AMPK ratio and the mRNA expressions of GLUT-2 and GYS2 in liver (P < 0.05). In addition, the metabolic pathway associated with the biosynthesis of unsaturated fatty acids was most significantly promoted (P < 0.05) by oral administration of SCFAs. Exogenous introduction of SCFAs might attenuate the fat deposition and to some extent improve the glucose control in the pig model, which occurred independently of the gut microbiota. Show less
📄 PDF DOI: 10.1186/s40104-021-00581-3
ANGPTL4
Huan Zhong, Jie Hu, Yi Zhou · 2021 · Genomics · Elsevier · added 2026-04-24
In this study, RNA sequencing was used to identify the hepatic gene expression profile in grass carp associated with luteinizing hormone-releasing hormone agonist (LHRH-A) treatment. A total of 93,912 Show more
In this study, RNA sequencing was used to identify the hepatic gene expression profile in grass carp associated with luteinizing hormone-releasing hormone agonist (LHRH-A) treatment. A total of 93,912,172 reads were generated by HiSeq 4000 sequencing platform. After filtering, 83,450,860 clean reads were mapped to the reference genome. By calculating the FPKM of genes, 1475 differentially expressed genes were identified. PPAR signaling pathway was enriched with upregulated genes in LHRH-A injection group showing the regulation of the lipid metabolism by LHRH-A. The expression of eight key genes in PPAR signaling pathway was confirmed by qPCR and the results suggested that ACSL4A, ACSL4B, ANGPTL4, LPL, RXRBA and SLC27A1B were significantly stimulated by LHRH-A injection. This investigation provides the evidence that LHRH-A could play a role in lipid metabolism. Show less
no PDF DOI: 10.1016/j.ygeno.2020.09.043
ANGPTL4
Tengda Huang, Lin Yu, Hongyuan Pan +10 more · 2021 · Frontiers in nutrition · Frontiers · added 2026-04-24
An excessive high-fat/energy diet is a major cause of obesity and linked complications, such as non-alcoholic fatty liver disease (NAFLD). Betaine has been shown to effectively improve hepatic lipid m Show more
An excessive high-fat/energy diet is a major cause of obesity and linked complications, such as non-alcoholic fatty liver disease (NAFLD). Betaine has been shown to effectively improve hepatic lipid metabolism. However, the mechanistic basis for this improvement is largely unknown. Herein, integration of mRNA sequencing and ribosome footprints profiling (Ribo-seq) was used to investigate the means by which betaine alleviates liver lipid metabolic disorders induced by a high-fat diet. For the transcriptome, gene set enrichment analysis demonstrated betaine to reduce liver steatosis by up-regulation of fatty acid beta oxidation, lipid oxidation, and fatty acid catabolic processes. For the translatome, 574 differentially expressed genes were identified, 17 of which were associated with the NAFLD pathway. By combined analysis of transcriptome and translatome, we found that betaine had the greater effect on NAFLD at the translational level. Further, betaine decreased translational efficiency (TE) for IDI1, CYP51A1, TM7SF2, and APOA4, which are related to lipid biosynthesis. In summary, this study demonstrated betaine alleviating lipid metabolic dysfunction at the translational level. The transcriptome and translatome data integration approach used herein provides for a new understanding of the means by which to treat NAFLD. Show less
📄 PDF DOI: 10.3389/fnut.2021.751436
APOA4
Jiawei Zhou, Yu Zhang, Junjing Wu +4 more · 2021 · Journal of proteomics · Elsevier · added 2026-04-24
Intramuscular fat (IMF) content is an important factor in porcine meat quality. Previous studies have screened multiple candidate genes related to IMF deposition, but the lipids that affect IMF deposi Show more
Intramuscular fat (IMF) content is an important factor in porcine meat quality. Previous studies have screened multiple candidate genes related to IMF deposition, but the lipids that affect IMF deposition and their lipid-protein network remain unknown. In this study, we performed proteomic and lipidomic analyses of the longissimus dorsi (LD) muscle from high-IMF (IMFH) and low-IMF (IMF-L) groups of Xidu black pigs. Eighty-eight proteins and 143 lipids were differentially abundant between the groups. The differentially abundant proteins were found to be involved in cholesterol metabolism, the PPAR signaling pathway, and ferroptosis. The triacylglycerols (TAGs) upregulated in the IMF-H group were mainly shown to be synthesized by saturated fatty acids (SFAs), while the downregulated TAGs were mainly synthesized by polyunsaturated fatty acids (PUFAs). All differentially abundant phosphatidylinositols (PIs) and phosphatidylserines (PSs) were found to be upregulated in the IMF-H group. A correlation analysis of the proteomic and lipidomic revealed candidate proteins (APOA4, VDAC3, PRNP, CTSB, GSPT1) related to TAG, PI, and PS lipids. These results revealed differences in proteins and lipids between the IMF-H and IMF-L groups, which represent new candidate proteins and lipids that should be investigated to determine the molecular mechanisms controlling IMF deposition in pigs. SIGNIFICANCE: Intramuscular fat (IMF) is a key factor affecting meat quality, and meat with a higher IMF content can have a better flavor. In this study, proteomic results show that the ferroptosis pathway, including the PRNP, VDAC3 and CP proteins, affects IMF deposition. Lipid composition is the key factor affecting IMF deposition, but there are few reports on this. In this study, through lipidomic analysis, we suggest that saturated fatty acid (SFA), phosphatidylinositol (PI), and phosphatidylserine (PS) may contribute to IMF deposition. A correlation analysis reveals the potential regulatory network between lipids and proteins. This study clarifies the difference in protein and lipid compositions in longissimus dorsi (LD) muscle with high and low IMF contents. This information suggests that it would be beneficial to increase the intramuscular fat content of pork not only from a genetic perspective but also from a nutritional perspective. Show less
no PDF DOI: 10.1016/j.jprot.2021.104235
APOA4
Xiaoming Li, Xiaohuan Liu, Yupeng Zhang +5 more · 2021 · Biochemical and biophysical research communications · Elsevier · added 2026-04-24
Apolipoprotein A4 (ApoA4) regulates lipid and glucose metabolism and exerts anti-inflammatory effects in atherogenesis and colitis. The present study explored the presumed protective role of ApoA4 in Show more
Apolipoprotein A4 (ApoA4) regulates lipid and glucose metabolism and exerts anti-inflammatory effects in atherogenesis and colitis. The present study explored the presumed protective role of ApoA4 in carbon tetrachloride (CCl4)-induced acute liver injury (ALI) in mice. The ALI model in wild type (WT), ApoA4 knock-out (ApoA4-KO) and ApoA4 transgenic (ApoA4-TG) mice was induced by a single intraperitoneal administration of CCl4. Liver and blood were harvested from mice to assess liver functions, immunohistological changes, immune cell populations and cytokine profiles. ApoA4 deficiency aggravated, and ApoA4 overexpression alleviated CCl4-inflicted liver damage by controlling levels of anti-oxidant enzymes. ApoA4 deletion increased the recruitment of monocytes/macrophages into the injured liver and upregulated the plasma levels of IL-6, TNF-α and MCP-1, but lower IL-10 and IFN-γ. ApoA4 over-expression rescued this effect and resulted in lower percentages of monocytes/macrophages and dendritic cells, the ratio of blood pro-inflammatory to anti-inflammatory monocytes and reduced plasma concentrations of IL-6, but enhanced IL-10 and IFN-γ. We propose ApoA4 as a potential new therapeutic target for the management of liver damage. Show less
no PDF DOI: 10.1016/j.bbrc.2020.11.024
APOA4
Qi Yang, Na Pu, Xiao-Yao Li +12 more · 2021 · Frontiers in genetics · Frontiers · added 2026-04-24
The etiology of hypertriglyceridemia (HTG) and acute pancreatitis (AP) is complex. Herein, we dissected the underlying etiology in a patient with HTG and AP. The patient had a 20-year history of heavy Show more
The etiology of hypertriglyceridemia (HTG) and acute pancreatitis (AP) is complex. Herein, we dissected the underlying etiology in a patient with HTG and AP. The patient had a 20-year history of heavy alcohol consumption and an 8-year history of mild HTG. He was hospitalized for alcohol-triggered AP, with a plasma triglyceride (TG) level up to 21.4 mmol/L. A temporary rise in post-heparin LPL concentration (1.5-2.5 times of controls) was noted during the early days of AP whilst LPL activity was consistently low (50∼70% of controls). His TG level rapidly decreased to normal in response to treatment, and remained normal to borderline high during a ∼3-year follow-up period during which he had abstained completely from alcohol. Sequencing of the five primary HTG genes (i.e., Show less
📄 PDF DOI: 10.3389/fgene.2021.640859
APOA5
Jun-Yu Zhou, Sunmin Park · 2021 · Journal of personalized medicine · MDPI · added 2026-04-24
3GO is a condition in which hypertension, hyperglycemia, and dyslipidemia co-occur, and these conditions are related to each other and genetic and environmental factors. We hypothesized that common ge Show more
3GO is a condition in which hypertension, hyperglycemia, and dyslipidemia co-occur, and these conditions are related to each other and genetic and environmental factors. We hypothesized that common genetic variants and their interactions with lifestyles influenced 3GO risk. We aimed to explore common genetic variants to affect 3GO risk and their haplotype interaction with lifestyles in a city hospital-based cohort in 58,701 Koreans > 40 years. 3GO was defined as SBP ≥ 140 mmHg and DBP ≥ 90 mmHg for hypertension, fasting blood glucose ≥ 126 mg/dL for hyperglycemia, and LDL ≥ 160 mg/dL or HDL ≤ 40 mg/dL, or triglyceride ≥ 200 mg/dL for dyslipidemia. Haplotypes were generated by genetic variants selected from genome-wide association study ((GWAS) an observational study of the genetic variation of the whole genome in different individuals, used to see if any variation is related to traits) after adjusting for age, sex, area of residence, and body mass index (BMI). Nutrient intakes were assessed using food frequency questionnaires. Interactions between haplotype and lifestyles and 3GO risk were investigated. Parameters related to metabolic syndrome were significantly different in the 0GO, 1-2GO, and 3GO groups, that is, groups of individuals with none, one to two, or all three of the components of 3GO. At the 11q23 locus, Show less
📄 PDF DOI: 10.3390/jpm11030207
APOA5
Huayao Li, Chundi Gao, Jing Zhuang +7 more · 2021 · Cancer biomarkers : section A of Disease markers · added 2026-04-24
Invasive breast cancer is a highly heterogeneous tumor, although there have been many prediction methods for invasive breast cancer risk prediction, the prediction effect is not satisfactory. There is Show more
Invasive breast cancer is a highly heterogeneous tumor, although there have been many prediction methods for invasive breast cancer risk prediction, the prediction effect is not satisfactory. There is an urgent need to develop a more accurate method to predict the prognosis of patients with invasive breast cancer. To identify potential mRNAs and construct risk prediction models for invasive breast cancer based on bioinformaticsMETHODS: In this study, we investigated the differences in mRNA expression profiles between invasive breast cancer and normal breast samples, and constructed a risk model for the prediction of prognosis of invasive breast cancer with univariate and multivariate Cox analyses. We constructed a risk model comprising 8 mRNAs (PAX7, ZIC2, APOA5, TP53AIP1,MYBPH, USP41, DACT2, and POU3F2) for the prediction of invasive breast cancer prognosis. We used the 8-mRNA risk prediction model to divide 1076 samples into high-risk groups and low-risk groups, the Kaplan-Meier curve showed that the high-risk group was closely related to the poor prognosis of overall survival in patients with invasive breast cancer. The receiver operating characteristic curve revealed an area under the curve of 0.773 for the 8 mRNA model at 3-year overall survival, indicating that this model showed good specificity and sensitivity for prediction of prognosis of invasive breast cancer. The study provides an effective bioinformatic analysis for the better understanding of the molecular pathogenesis and prognosis risk assessment of invasive breast cancer. Show less
no PDF DOI: 10.3233/CBM-201684
APOA5
Jun Zhou, Zhuoying Ren, Jie Xu +2 more · 2021 · Medical review (2021) · added 2026-04-24
Gene editing nucleases (GENs), represented by CRISPR/Cas9, have become major tools in biomedical research and offer potential cures for many human diseases. Gene editing therapy (GETx) studies in anim Show more
Gene editing nucleases (GENs), represented by CRISPR/Cas9, have become major tools in biomedical research and offer potential cures for many human diseases. Gene editing therapy (GETx) studies in animal models targeting genes such as proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein C3 (APOC3), angiopoietin Like 3 (ANGPTL3) and inducible degrader of the low-density lipoprotein receptor (IDOL) have demonstrated the benefits and advantages of GETx in managing atherosclerosis. Here we present our views on this brand new therapeutic option for cardiovascular diseases (CVD). Show less
📄 PDF DOI: 10.1515/mr-2021-0010
APOC3
Huan Wang, Xiaomin Huang, Pengfei Xu +8 more · 2021 · Metabolism: clinical and experimental · Elsevier · added 2026-04-24
Apolipoprotein C3 (ApoC3) is a regulator of triglyceride metabolism and inflammation, and its plasma levels are positively correlated with the progression of diabetic nephropathy (DN) in patients. How Show more
Apolipoprotein C3 (ApoC3) is a regulator of triglyceride metabolism and inflammation, and its plasma levels are positively correlated with the progression of diabetic nephropathy (DN) in patients. However, the role and underlying mechanism of ApoC3 in DN remain unclear. Diabetes was induced in ApoC3 transgenic (Tg) and knockout (KO) mice by injection of streptozotocin. We studied the effect of ApoC3 on type 1 DN after 4 months of diabetes. Plasma glucose and lipid levels, renal function parameters and inflammation- and fibrogenesis-related gene and protein expression levels were studied. In vitro, human mesangial cells (HMCs) were incubated with high levels of glucose or/and triglyceride-rich lipoproteins (TRLs) with a high or low ApoC3 content isolated from Tg or wild-type (WT) mice, respectively, to explore the mechanisms of ApoC3 on development of DN. We found that compared to WT mice, Tg mice exhibited hypertriglyceridemia (HTG), aggravated early renal function injury and inflammation, enlarged glomerular and mesangial surface areas, renal lipid deposition and elevated fibrogenesis-related gene expression levels after 4 months of diabetes. ApoC3 overexpression activated the renal Toll-like receptor 2 (TLR2) and nuclear factor-κB (NF-κB) signaling pathways and increased the renal gene and protein expression levels of the downstream inflammatory factors TNF-α, VCAM-1 and MCP-1. Unfortunately, we did not find that ApoC3 deficiency had an obvious protective effect against DN. In vitro, we found that TRLs with a high ApoC3 content increased the gene and protein expression levels of inflammation- and fibrogenesis-related factors in HMCs compared to those following administration of the same concentration of TRLs with a low ApoC3 content. These effects of ApoC3 were inhibited by blockade of TLR2 or NF-κB. These findings suggest that ApoC3 aggravates early-stage DN by activating the renal TLR2/NF-κB pathway which is partially independent of HTG. Show less
no PDF DOI: 10.1016/j.metabol.2021.154740
APOC3
Shuo Wang, Huasheng Shi, Tao Liu +13 more · 2021 · Hepatobiliary surgery and nutrition · added 2026-04-24
Hepatocellular carcinoma (HCC) is one of the most common causes of cancer worldwide. Although many studies have focused on oncogene characteristics, the genomic landscape of Chinese HCC patients has n Show more
Hepatocellular carcinoma (HCC) is one of the most common causes of cancer worldwide. Although many studies have focused on oncogene characteristics, the genomic landscape of Chinese HCC patients has not been fully clarified. A total of 165 HCC patients, including 146 males and 19 females, were enrolled. The median age was 55 years (range, 27-78 years). Corresponding clinical and pathological information was collected for further analysis. A total of 168 tumor tissues from these patients were selected for next-generation sequencing (NGS)-based 450 panel gene sequencing. Genomic alterations including single nucleotide variations (SNV), short and long insertions and deletions (InDels), copy number variations, and gene rearrangements were analyzed. Tumor mutational burden (TMB) was measured by an algorithm developed in-house. The top quartile of HCC was classified as TMB high. A total of 1,004 genomic alterations were detected from 258 genes in 168 HCC tissues. TMB values were identified in 160 HCC specimens, with a median TMB of 5.4 Muts/Mb (range, 0-28.4 Muts/Mb) and a 75% TMB of 7.7 Muts/Mb. The most commonly mutated genes were The most frequently mutated genes of HCC patients in China were Show less
no PDF DOI: 10.21037/hbsn.2019.09.17
AXIN1
Zaoqu Liu, Yuyuan Zhang, Chengcheng Shi +5 more · 2021 · Journal of translational medicine · BioMed Central · added 2026-04-24
The tumor immunological microenvironment (TIME) has a prominent impact on prognosis and immunotherapy. However, the heterogeneous TIME and the mechanisms by which TIME affects immunotherapy have not b Show more
The tumor immunological microenvironment (TIME) has a prominent impact on prognosis and immunotherapy. However, the heterogeneous TIME and the mechanisms by which TIME affects immunotherapy have not been elucidated in hepatocellular carcinoma (HCC). A total of 2195 eligible HCC patients from TCGA and GEO database were collected. We comprehensively explored the different heterogeneous TIME phenotypes and its clinical significance. The potential immune escape mechanisms and what genomic alterations may drive the formation of different phenotypes were further investigated. We identified three phenotypes in HCC: TIME-1, the "immune-deficiency" phenotype, with immune cell depletion and proliferation; TIME-2, the "immune-suppressed" phenotype, with enrichment of immunosuppressive cells; TIME-3, the "immune-activated phenotype", with abundant leukocytes infiltration and immune activation. The prognosis and sensitivity to both sorafenib and immunotherapy differed among the three phenotypes. We also underlined the potential immune escape mechanisms: lack of leukocytes and defective tumor antigen presentation capacity in TIME-1, increased immunosuppressive cells in TIME-2, and rich in immunoinhibitory molecules in TIME-3. The different phenotypes also demonstrated specific genomic events: TIME-1 characterized by TP53, CDKN2A, CTNNB1, AXIN1 and FOXD4 alterations; TIME-2 characterized by significant alteration patterns in the PI3K pathway; TIME-3 characterized by ARID1A mutation. Besides, the TIME index (TI) was proposed to quantify TIME infiltration pattern, and it was a superior prognostic and immunotherapy predictor. A pipeline was developed to classify single patient into one of these three subtypes and calculated the TI. We identified three TIME phenotypes with different clinical outcomes, immune escape mechanisms and genomic alterations in HCC, which could present strategies for improving the efficacy of immunotherapy. TI as a novel prognostic and immunotherapeutic signature that could guide personalized immunotherapy and clinical management of HCC. Show less
📄 PDF DOI: 10.1186/s12967-020-02697-y
AXIN1
Zhi-Qiang Hu, Hao-Yang Xin, Chu-Bin Luo +4 more · 2021 · Cancer immunology, immunotherapy : CII · Springer · added 2026-04-24
Recent studies suggested that the immune microenvironment and mutational landscape are associated with the response to immune-based therapy in several types of cancer. The roles of those factors in Ch Show more
Recent studies suggested that the immune microenvironment and mutational landscape are associated with the response to immune-based therapy in several types of cancer. The roles of those factors in Chinese HCC remain largely unknown. In this study, we obtained 182 FFPE samples of HCC cohort that were previously subjected to NGS (49 WGS, 18 WES, and 115 targeted sequencing). We performed immunohistochemistry to detect CD3, CD4, CD8, CD57, Foxp3, CD68, CD66b, and PD-L1 expression in the samples. We identified diverse associations between the mutational landscape and the immune microenvironment in the HCC samples. High mutational burden and an aristolochic acid-dominated mutational signature were both correlated with elevated tumoral PD-L1 expression and CD3+ T-cell infiltration and high numbers of CD68+ TAMs and CD66b+ TANs. CD4+ and CD8+ T cells exhibited lower infiltration levels in tumors with mutations in AXIN1/CTNNB1 and in tumors with aflatoxin-dominant mutational signatures. Moreover, tumors with TP53 mutations had less CD8+ T-cell infiltration and more Foxp3+ Treg-cell infiltration than those without TP53 mutations. Kaplan-Meier survival analysis revealed that the presence of CD8+, Foxp3+, CD66b+, or CD68+ immune cells; tumoral PD-L1 expression alone; or the presence of CD8+ or Foxp3+ cells combined with TP53 mutation were predictive of recurrence and poor overall survival after curative resection. In conclusion, the association between the mutational landscape and the immune microenvironment warrants further analysis to determine its impact on patient outcomes to guide personalized immune-based therapy for Chinese patients with HCC. Show less
no PDF DOI: 10.1007/s00262-020-02685-7
AXIN1
Jian Zhou, Ziyuan Chen, Ming Zou +6 more · 2021 · Frontiers in oncology · Frontiers · added 2026-04-24
Chromobox family genes (CBXs) are known to play roles in numerous modifications of the chromatin in order to inhibit the transcription of target genes. CBXs have been shown to be expressed at high lev Show more
Chromobox family genes (CBXs) are known to play roles in numerous modifications of the chromatin in order to inhibit the transcription of target genes. CBXs have been shown to be expressed at high levels in many types of cancer and can also serve as a target gene for therapeutic purposes. However, little is known about the expression and prognostic value of CBXs in human sarcomas. The transcription level of CBXs was analyzed using the Oncomine dataset, and the differential expression of CBXs in sarcoma was reported by the Gene Expression Profiling Interactive Analysis (GEPIA) dataset. We also used the CCLE dataset to evaluate the expression of CBXs in a sarcoma cell line. The prognostic value of CBXs was analyzed using GEPIA and Kaplan-Meier analysis. In addition, the corrections between CBXs and their co-expressed genes were reported using Oncomine and GEPIA datasets. DAVID was used to perform GO function enrichment analysis for the CBXs and their co-expression genes. Finally, TIMER was used to analyze the immune cell infiltration of CBXs in patients with sarcoma. HP1- The results from the present study indicated that CBXs were significantly associated with prognosis and immunological status in sarcoma. These data suggest that CBXs could serve as potential biomarkers for prognosis and immune infiltration in human sarcoma. Show less
📄 PDF DOI: 10.3389/fonc.2021.657595
CBX1
Weimin Wang, Ke Min, Gaoyang Chen +5 more · 2021 · Journal of Cancer · added 2026-04-24
📄 PDF DOI: 10.7150/jca.58768
CETP
Ruihai Zhou, George A Stouffer, Sidney C Smith · 2021 · Journal of cardiovascular pharmacology and therapeutics · SAGE Publications · added 2026-04-24
Hypercholesterolemia is a well-established risk factor for atherosclerotic cardiovascular disease (ASCVD). Low-density lipoprotein cholesterol (LDL-C) has been labeled as "bad" cholesterol and high-de Show more
Hypercholesterolemia is a well-established risk factor for atherosclerotic cardiovascular disease (ASCVD). Low-density lipoprotein cholesterol (LDL-C) has been labeled as "bad" cholesterol and high-density lipoprotein cholesterol (HDL-C) as "good" cholesterol. The prevailing hypothesis is that lowering blood cholesterol levels, especially LDL-C, reduces vascular deposition and retention of cholesterol or apolipoprotein B (apoB)-containing lipoproteins which are atherogenic. We review herein the clinical trial data on different pharmacological approaches to lowering blood cholesterol and propose that the mechanism of action of cholesterol lowering, as well as the amplitude of cholesterol reduction, are critically important in leading to improved clinical outcomes in ASCVD. The effects of bile acid sequestrants, fibrates, niacin, cholesteryl ester transfer protein (CETP) inhibitors, apolipoprotein A-I and HDL mimetics, apoB regulators, acyl coenzyme A: cholesterol acyltransferase (ACAT) inhibitors, cholesterol absorption inhibitors, statins, and proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors, among other strategies are reviewed. Clinical evidence supports that different classes of cholesterol lowering or lipoprotein regulating approaches yielded variable effects on ASCVD outcomes, especially in cardiovascular and all-cause mortality. Statins are the most widely used cholesterol lowering agents and have the best proven cardiovascular event and survival benefits. Manipulating cholesterol levels by specific targeting of apoproteins or lipoproteins has not yielded clinical benefit. Understanding why lowering LDL-C by different approaches varies in clinical outcomes of ASCVD, especially in survival benefit, may shed further light on our evolving understanding of how cholesterol and its carrier lipoproteins are involved in ASCVD and aid in developing effective pharmacological strategies to improve the clinical outcomes of ASCVD. Show less
no PDF DOI: 10.1177/10742484211023632
CETP
Enchen Zhou, Zhuang Li, Hiroyuki Nakashima +5 more · 2021 · Pharmacological research · Elsevier · added 2026-04-24
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition, by increasing hepatic low density lipoprotein (LDL) receptor (LDLR) levels, has emerged as a strategy to reduce atherosclerosis by low Show more
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition, by increasing hepatic low density lipoprotein (LDL) receptor (LDLR) levels, has emerged as a strategy to reduce atherosclerosis by lowering circulating very low density lipoprotein (VLDL)-cholesterol. We hypothesized that the therapeutic effectiveness of PCSK9 inhibition can be increased by accelerating the generation of VLDL remnants, which typically have a high affinity for the LDLR. Therefore, we aimed to investigate whether accelerating lipolytic processing of VLDL by brown fat activation can further lower (V)LDL and reduce atherosclerosis on top of PCSK9 inhibition. APOE*3-Leiden.CETP mice were fed a Western-type diet and treated with the anti-PCSK9 antibody alirocumab or saline. After 2 weeks, both groups of mice were randomized to receive either the selective β3-adrenergic receptor (AR) agonist CL316,243 to activate brown fat or saline for 3 additional weeks to evaluate VLDL clearance or 12 additional weeks to analyze atherosclerosis development. β3-AR agonism and alirocumab combined decreased (V)LDL-cholesterol compared to alirocumab alone, which was explained by an accelerated plasma clearance of VLDL-cholesteryl esters that were mainly taken up by the liver. In addition, the combination promoted the transfer of VLDL-phospholipids to HDL to a higher extent than alirocumab alone, accompanied by higher plasma HDL-cholesterol levels and increased cholesterol efflux capacity. Consequently, combination treatment largely reduced atherosclerotic lesion area compared to vehicle. Together, β3-AR agonism enhances the lipoprotein-modulating effects of alirocumab to further improve dyslipidemia and non-significantly further attenuate atherosclerosis development. Our findings demonstrate that brown fat activation may enhance the therapeutic effects of PCSK9 inhibition in dyslipidemia. Show less
no PDF DOI: 10.1016/j.phrs.2021.105524
CETP
Enchen Zhou, Zhuang Li, Hiroyuki Nakashima +7 more · 2021 · Arteriosclerosis, thrombosis, and vascular biology · added 2026-04-24
[Figure: see text].
no PDF DOI: 10.1161/ATVBAHA.121.315882
CETP
Shuai-Nan Zhang, Ya-Feng He, Xu-Zhao Li +2 more · 2021 · Computers in biology and medicine · Elsevier · added 2026-04-24
Previous studies have shown that Sophorae Tonkinensis radix et rhizome (ST) can be used to treat some lung diseases. However, the therapeutic potentials, therapeutic advantages, mechanism of action, a Show more
Previous studies have shown that Sophorae Tonkinensis radix et rhizome (ST) can be used to treat some lung diseases. However, the therapeutic potentials, therapeutic advantages, mechanism of action, and material basis of ST treatment of lung diseases remain unclear. Thus, the aim of this study was to carry out an integrated analysis based on the biolabel-led research pattern. Proteomics and metabonomics were applied to explore the biolabels responsible for the effect of ST on lung tissue. Based on the biolabels, a bioinformatics database was used to topologically analyze the therapeutic potentials, therapeutic advantages, mechanism of action, and material basis of ST in treating lung diseases. Four human lung-cancer cell models were used to validate the results of the biolabel analysis. In total, 45 proteins and 3 metabolites were significantly enriched in 13 pathways and were considered as biolabels. Bioinformatics revealed that the therapeutic potentials of ST involved a variety of lung diseases, especially lung neoplasms. Under the mediation of 40 biolabels, 29 compounds may be the material basis of ST in treating lung diseases. In a verification experiment, ST had a significant inhibitory effect on the H226 cell line (lung squamous cell carcinoma), which ranks first in morbidity and mortality among lung cancers in China. Additionally, five biolabels (CPS1, CKM, CPT1B, COX5B, and COX4I1) were involved in the anti-lung cancer mechanism of ST and 3 compounds (gallic acid, betulinic acid, and caffeic acid). These findings indicate that the biolabel-led research pattern was helpful in achieving the objectives of this study. Show less
no PDF DOI: 10.1016/j.compbiomed.2021.104769
CPS1